ESYA Labs has entered a collaboration with Alamar Biosciences for biomarker detection and quantification for inflammatory and neurological diseases.

This partnership will leverage Alamar’s ARGO HT System and NULISA platform, as well as ESYA’s expertise in lysosomal biology and machine learning-driven diagnostics.

The technologies will be accessible through ESYA’s lab in Dallas, Texas, US.

As a certified service provider for Alamar, ESYA will offer tailored assay solutions to assist pharmaceutical companies in creating treatments for various neurological, inflammatory, and neurodegenerative conditions, including frontotemporal dementia (FTD), Alzheimer’s, amyotrophic lateral sclerosis (ALS), Parkinson’s, among other conditions of central and peripheral nervous system.

The partnership is also set to combine ESYA's insights in multi-omics and computational analytics with Alamar's immunoassay technology.

ESYA Labs CEO Dhivya Venkat said: “Our partnership with Alamar marks a milestone in our mission to redefine precision diagnostics.

“By integrating ESYA’s cutting-edge platforms with Alamar’s innovative assay systems, we’re poised to deliver transformative tools for addressing the challenges of neurodegenerative diseases.”

Alamar Biosciences founder, chairman and CEO Yuling Luo said: “We are thrilled to partner with ESYA labs. The integration of Alamar’s novel NULISA biomarker assays into their multi-omics platform will advance the field of testing for neurodegeneration diseases.”

A fully automated, high-throughput proteomics platform, the ARGO HT System is designed for ultra-high sensitivity and multiplexed analysis. It allows for extensive biomarker profiling, validation, and clinical translation.

It features a turnkey instrument with an integrated qPCR system, a fully automated workflow with less than 30 minutes of hands-on time, and a high throughput capacity that can process up to 288 samples per run batch.

Results can be delivered in less than eight hours for single-plex qPCR assays and under 15 hours for multiplex next-generation sequencing (NGS) assays, with integrated software for data analysis.

The NULISA Platform, part of this collaboration, brings attomolar sensitivity to proteomic analysis.

Utilising a capture and release mechanism and the latest advances in NGS, the platform is set to offer both ultra-high sensitivity and scalable multiplexing.